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Abstract
Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number
gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). This
locus has been found by multiple genome wide association studies to be associated with lung cancer in both smokers and
non-smokers. CLPTM1L has been identified as an overexpressed protein in human ovarian tumor cell lines that are resistant
to cisplatin, which is the only insight thus far into the function of CLPTM1L. Here we find CLPTM1L expression to be
increased in lung adenocarcinomas compared to matched normal lung tissues and in lung tumor cell lines by mechanisms
not exclusive to copy number gain. Upon loss of CLPTM1L accumulation in lung tumor cells, cisplatin and camptothecin
induced apoptosis were increased in direct proportion to the level of CLPTM1L knockdown. Bcl-xL accumulation was
significantly decreased upon loss of CLPTM1L. Expression of exogenous Bcl-xL abolished sensitization to apoptotic killing
with CLPTM1L knockdown. These results demonstrate that CLPTM1L, an overexpressed protein in lung tumor cells, protects
from genotoxic stress induced apoptosis through regulation of Bcl-xL. Thus, this study implicates anti-apoptotic CLPTM1L
function as a potential mechanism of susceptibility to lung tumorigenesis and resistance to chemotherapy.
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Introduction
CLPTM1L is so named based on its homology with Cleft Lip
and Palate Transmembrane Protein 1, which was identified as
disrupted in a family with cleft lip and palate [1]. CLPTM1L was
identified as an up-regulated transcript in a cisplatin resistant
ovarian tumor cell line [2]. However, interpretation of the results
of this study is difficult, as there is no implication of mechanism
and the effect of overexpression of CLPTM1L in cisplatin
sensitivity was conflicting in different ovarian tumor cell lines,
depending on their pre-existing level of resistance. Nevertheless, a
role for CLPTM1L in resistance to cisplatin was suggested.
Interestingly, the homologue CLPTM1 has been found to be
expressed at higher levels in doxorubicin resistant breast tumors,
and expression of CLPTM1 is predictive of response to
doxorubicin [3]. A recent study found that a genetic variant
within the CLPTM1L gene (rs402710) is associated with the
accumulation of DNA adducts in tumor adjacent lung tissue [4].
This same SNP, among others in the region of the CLPTM1L and
TERT genes is associated with risk of lung cancer [5,6,7]. In a
recent study on cervical cancer integrating gene dosage and
expression data, the CLPTM1L/TERT locus was found to have
copy number gain in tumors and expression patterns that
correlated with copy number gain [8]. Another recent study
revealed that with copy number gain across 5p, CLPTM1L
expression was increased approximately 5 fold in cervical cancer
cell lines over normal cervical epithelial cells, while expression of
the other genes at 5p15.33 was not changed [9]. These insights
into the function of CLPTM1L, and the fact that copy number
gain of the region of chromosome 5p containing CLPTM1L is the
most frequent cytogenetic event in the early stages of non-small
cell lung cancer (NSCLC) [10] are compelling justification for the
study of the role of CLPTM1L in lung cancer as well as other
cancer types.
DNA damage, such as that caused by genotoxic chemother-
apeutic agents, induces apoptosis through double stranded break
associated kinases, and subsequent transcriptional regulation of
apoptotic effectors primarily through p53 [11]. Bcl-2 family
members regulated by p53 including Bax are central to the
activation of apoptosis by this pathway and act by permeabiliz-
ing the mitochondrial membrane [12]. Anti-apoptotic Bcl-2
family member Bcl-xL protects cancer cells from p53 induced
apoptosis [13] and acts through the binding and inactivation of
Bax [14] and binding of proteins that recruit Bax to the
mitochondrial membrane [15]. Bcl-xL is frequently overex-
pressed in lung tumors, is associated with poor prognosis
[16,17] and plays an important role in resistance to genotoxic
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[18,19,20,21,22,23].
Although a connection of CLPTM1L to cancer is suggested by
copy number gain, genome wide association and studies in ovarian
tumor cell lines; the function of CLPTM1L and its role in
tumorigenesis is thus far unknown. Here we report that
CLPTM1L is a commonly overexpressed anti-apoptotic factor in
lung tumors. Knockdown of CLPTM1L transcript in NSCLC cells
results in an increase in sensitivity to genotoxic stress mediated
apoptotic killing and diminishes expression of Bcl-xL in a manner
dependent on the dose of CLPTM1L expression. Moreover,
expression of exogenous Bcl-xL abolishes sensitization to genotoxic
stress induced apoptosis by CLPTM1L knockdown. This protec-
tive effect is not exclusive to cisplatin mediated killing. Rather,
CLPTM1L acts indirectly as a general inhibitor of the mitochon-
drial pathway of apoptosis through Bcl-xL regulation. These
results demonstrate a role for CLPTM1L in chemotherapeutic
resistance in lung tumor cells, and suggest a role for CLPTM1L in
lung tumorigenesis via protection from apoptosis through
increased accumulation of Bcl-xL.
Results
Expression of CLPTM1L in Lung Tumors
Given reports of copy number gain in lung cancer, GWAS
evidence, and increased expression of CLPTM1L in cisplatin
resistant ovarian tumor cells, we sought to determine if CLPTM1L
was overexpressed in lung tumors. Expression of CLPTM1L
mRNA in NSCLC patient tumors was compared to that of
matched tumor-adjacent tissues by qPCR. CLPTM1L was
increased by an average of 2.24 fold reaching an overall
significance for differential expression in 30 Stage I NSCLC
patients (p =.0028, Two-tailed Student’s T-Test) (Figure 1A).
Although TERT expression was an average of 1.76 fold higher in
tumor tissues, overall differences in TERT expression did not
reach significance and were not significantly correlated with
CLPTM1L expression (r
2=0.0018, p=0.994) (Figure S1A). The
sample consisted of 22 adenocarcinoma and 8 squamous cell
carcinoma patients Table S1 describes the known characteristics of
the study population. There was no difference in tumor over-
expression between squamous cell carcinomas and adenocarcino-
mas (data not shown). Analysis of expression microarray data from
148 lung tumor cell lines and 59 ‘‘normal’’ cell lines immortalized
with TERT and Cdk4 confirmed these results, revealing a 2.02
fold average difference in CLPTM1L expression compared to
immortalized cell lines (p =1.48E-9, Two-tailed Student’s T-Test)
(Figure 1B). This data also demonstrates that expression of
CLPTM1L is increased in tumor cells by mechanisms other than
copy number variation, as analysis excluding those tumor cell lines
with copy number variation remained significant (p =1.28E-8,
Two-tailed Student’s T-Test) and similar in magnitude (1.83 fold)
(Figure 1C). Copy number change was identical between
CLPTM1L and TERT genes. However, no correlation between
CLPTM1L expression and TERT expression was observed within
tumor cell lines (r
2=0.0126, p=0.175) (Figure S1B). Analysis of
expression was also conducted for different lung tumor subtypes.
Adenocarcinoma cell lines showed an average 2.15 fold greater
CLPTM1L expression over normal immortalized cell lines
(p=3.59E-7, Two-tailed Student’s T-Test) and Small Cell Lung
Cancer cell lines showed an average 2.07 fold greater expression
(p=1.15E-9, Two-tailed Student’s T-Test) (Figure 1D). Therefore,
increased CLPTM1L expression appears to be a feature of lung
tumors regardless of subtype.
CLPTM1L Confers Resistance to Genotoxic Stress Induced
Apoptosis in Lung Tumor Cells
Since increased expression of CLPTM1L is associated with lung
tumors, we aimed to modulate CLPTM1L levels in the lung
adenocarcinoma cell lines and determine the response to
genotoxic agents. Knockdown of CLPTM1L in A549 and H838
lung adenocarcinoma cell lines was performed using three
independent viral shRNA vectors and resulted in a range of
efficiencies up to 90% as measured by quantitative real-time PCR
and by immunoblot (Figure 2A and B). The effect of CLPTM1L
knockdown on killing by cisplatin was determined in these cell
lines. Cells were counted, plated in equal numbers at approxi-
mately 50% confluence, and assayed for viability by cell counting
after 48 hours of cisplatin treatment. Killing of lung tumor cells by
cisplatin was increased upon loss of CLPTM1L in a dose
dependent manner, ranging from 53% viability in A549 cells with
vector alone to 12% viability in cells with shCLPTM1L-3
(Figure 2C). Similarly, we induced apoptosis in A549 cells with
stable knockdown of CLPTM1L using camptothecin, a topoisom-
erase I inhibitor A549 cells were plated in equal numbers and
assayed for viability by MTS assay after 48 hours of treatment with
camptothecin. Again, loss of CLPTM1L through shRNA knock-
down sensitized lung tumor cells to dose dependent apoptotic
killing in a manner consistent with the level of CLPTM1L
expression (Figure S2), demonstrating that the anti-apoptotic
effects of CLPTM1L is not exclusive to cisplatin. Similar results
were observed in H838 cells, which demonstrated increased
sensitivity to camptothecin induced killing upon knockdown of
CLPTM1L expression (Figure 2D). Consistent with these findings,
exogenous over-expression of CLPTM1L in H1299 cells, which
were determined to express relatively low levels of endogenous
CLPTM1L transcript compared to A549 cells by microarray
analysis (data not shown), resulted an increase in cell viability from
27% with vector alone to 36% with CLPTM1L over-expression
(p.0.04) after treatment with camptothecin relative to DSMO
solvent controls (Figure 2E).
Annexin V immunofluorescence detected by flow cytometry
was used as a marker of early apoptosis in A549 cells with or
without CLPTM1L knockdown and cisplatin treatment. We
observed a dose dependent increase in apoptosis with loss of
CLPTM1L (Figure 3A). While only 16% of cells with vector alone
were apoptotic after 10mM cisplatin treatment for 24 hours, 76%
of cells with shCLPTM1L-3 were apoptotic. Resistance to cisplatin
induced apoptosis was found to be proportional to the amount of
CLPTM1L transcript accumulation in these cells, with an r
2 of
0.9808 (p=2610
28) between percent knockdown and percent
apoptotic cells (Figure S3A). Cisplatin concentrations at the lower
limits of sensitivity were used to allow resolution of sensitivities
conferred by different levels of CLPTM1L knockdown. The DNA
damaging agents cisplatin and nitrosamine 4-(methyl-nitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK) both caused accumulation
of DNA strand breaks independently of CLPTM1L expression as
detected by the COMET method (Figure S4). Therefore, the
observed increase in sensitivity to cisplatin upon loss of CLPTM1L
is due to an effect on apoptosis or apoptotic signaling rather than
an effect on levels of acute DNA damage. Sensitivity to cisplatin
induced apoptosis was also increased with loss of CLPTM1L
expression by shRNA in H838 tumor cells (Figure 3B), measured
by colorimetric Caspase 3/7 activity assay. Again resistance to
cisplatin induced apoptosis was proportional to the amount of
CLPTM1L transcript accumulation in the cells, with an r
2 of
0.8847 (p=1.3610
24) between percent knockdown and relative
caspase 3 activity (Figure S3B). The appearance of cells in culture
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apoptosis upon loss of CLPTM1L (Figure 3C).
Regulation of Bcl-xL Expression is Essential for CLPTM1L
Effects on Apoptosis
To investigate the mechanism of CLPTM1L protection from
apoptosis, we measured protein levels of apoptotic regulators in
untreated A549 cells compared to those treated with cisplatin.
For evaluation of the requirement of CLPTM1L for regulation of
apoptosis, the most effective knockdown constructs in A549 cells
(sh2 and sh3) were evaluated. Treatment of A549 cells with
20 mM cisplatin induced accumulation of p53 and the pro-
apoptotic p53 target, Bax, and decreased accumulation of the
anti-apoptotic protein Bcl-2, consistent with the DNA damage
induced intrinsic apoptotic pathway (Figure 4A). Expression of
these apoptotic regulators was unaffected by knockdown of
CLPTM1L alone. However, the anti-apoptotic protein Bcl-xL,
while unaffected by cisplatin treatment in A549 cells, was
decreased when CLPTM1L levels were squelched by shRNA
expression. Knockdown of CLPTM1L with shRNAs reduced
Bcl-xL protein levels by 81% and 76% in cisplatin treated cells
(p,0.003, Two-tailed Student’s T-Test) as measured by three
independent Western analyses (Figure 4B). We therefore stably
expressed exogenous Bcl-xL in cells with and without knockdown
of CLPTM1L to evaluate the role of Bcl-xL in CLPTM1L
protection from apoptosis. Re-expression of Bcl-xL was con-
firmed by Western blot (Figure 4C). While knockdown of
CLPTM1L increased apoptosis in empty vector transfected cells
by 71%, exogenous Bcl-xL eliminated the CLPTM1L dependent
apoptosis (Figure 4D). Resistance to genotoxic stress induced
apoptosis closely corresponded to Bcl-xL levels, and Bcl-xL
Figure 1. Expression of CLPTM1L is increased in lung adenocarcinomas and in lung tumor cell lines. A) CLPTM1L transcript
accumulation as measured by qPCR in lung adenocarcinoma tissues relative to the mean of matched normal tumor adjacent tissue in 30 patients
demonstrating a 2.23 fold average increase in expression in tumor tissues. B) CLPTM1L transcript accumulation as measured by microarray in lung
tumor cell lines relative to the mean of non-transformed immortalized cell lines demonstrating a 2.02 fold average increase in expression in tumor cell
lines. C) Cell line expression data excluding those tumor cell lines with copy number variation demonstrating a 1.83 fold increase in tumor cell lines.
D) Cell line divided into adenocarcinoma cell lines and small cell lung cancer cell lines. Black bars represent average values. p-values were obtained
using a two-tailed Student’s T-Test.
doi:10.1371/journal.pone.0036116.g001
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stress induced apoptosis by CLPTM1L.
Discussion
Survival of cells undergoing DNA damage from genomic
instability or genotoxic stress leads to the accumulation of genetic
lesions characterizing human tumors. Abrogation of cell-cycle
checkpoint and apoptotic safeguards against replication of
damaged DNA is a hallmark of cancer. The result of protection
against DNA damage induced apoptosis includes both vulnerabil-
ity to unchecked somatic mutation and decreased sensitivity to
radiotherapy and chemotherapy. The previously referenced study
by Zienolddinny et al. suggests that CLPTM1L polymorphisms
may affect DNA damage accumulation [4]. Based on our
observations, it is plausible that protection from apoptosis by
CLPTM1L contributes to accumulation of DNA damage, thereby
conferring susceptibility to tumorigenesis. An alternative hypoth-
esis is that CLPTM1L plays a role in recognition or repair of DNA
damage, affecting the accumulation of such damage. Another is
that CLPTM1L directly influences the amount of DNA damage
that is incurred by genotoxic agents. Our data (Figure S4) suggests
that CLPTM1L expression does not directly affect levels of acute
DNA damage incurred by cisplatin or NNK. Moreover, the
current study demonstrates that CLPTM1L has an apoptotic role
downstream of DNA damage and through regulation of Bcl-xL
expression, which is likely to affect accumulation of DNA damage.
The observation of differential accumulation of Bcl-xL upon
modulation of CLPTM1L expression, along with reconstitution of
an apoptosis resistant phenotype with expression of exogenous Bcl-
xL, provide evidence that CLPTM1L acts upstream of Bcl-xL to
confer resistance to genotoxic stress induced apoptosis. In
Figure 2. Loss of CLPTM1L sensitizes lung tumor cells to genotoxic agents. A) Knockdown of CLPTM1L expression in A549 cells via stable
shRNA. Confirmation of knockdown by western blot (inset). B) Knockdown of CLPTM1L expression in H838 cells via stable shRNA. Confirmation of
knockdown by western blot (inset). C) Relative cell viability of A549 cells with CLPTM1L knockdown after 48 hours treatment with media or cisplatin.
D) Relative cell viability of H838 cells with CLPTM1L knockdown after 48 hours treatment with DMSO vehicle or 1 mM camptothecin. E) Relative cell
viability of H1299 cells with CLPTM1L over-expression after 48 hours treatment with DMSO vehicle or 10 mM camptothecin. Error bars represent one
standard deviation from the mean of biological triplicates.
doi:10.1371/journal.pone.0036116.g002
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xL is expressed in vector containing cells than was observed in
previous experiments, although decreased accumulation in cells
with CLPTM1L knockdown remains evident. Concurrently,
apoptotic killing is slightly more robust in vector containing cells
observed in previous experiments, but the trend of increased
sensitivity upon loss of CLPTM1L and Bcl-xL remains. Impor-
tantly, this study shows that the anti-apoptotic function of
CLPTM1L is not exclusive to cisplatin sensitivity, but is a general
inhibition of the mitochondrial pathway of apoptosis.
Common overexpression of CLPTM1L in tumors supports the
notion of an oncogenic or tumor promoting role for CLPTM1L in
lung cancers. Protein expression studies performed and annotated
by the Human Protein Atlas project [24] confirm our findings.
Immunohistochemistry on human normal alveolar cells and lung
tumors demonstrated negative expression of CLPTM1L in normal
tissues, while expression in 12 lung tumors averaged a score of 1.91
on a scale of 0–3 (Figure S5). A score of 0 is negative, 1 is ‘‘weak’’,
2 is ‘‘moderate’’ and 3 is ‘‘strong’’. Six of these patients were
diagnosed with squamous cell carcinoma and six were diagnosed
with adenocarcinoma. No significant difference in expression
between the two pathologies was observed. A total of 66 normal
tissues from various organs scored an average of 0.98 (weak). None
of the lung tumors tested were negative. Lung tumor cell lines
A549 (NSCLC) and SCLC-21H (small cell) showed strong staining
and moderate staining, respectively.
Microarray data from tumor and immortalized cell lines
demonstrates that mechanisms other than copy number gain
result in increased expression in a subset of tumors. In genome
wide associations, the 5 p15.33 locus accounts for the greatest
contribution to lung cancer risk of three known loci in humans [6].
The 5 p locus is also implicated in cutaneous squamous cell
carcinoma and melanoma [25], ovarian cancer [26], testicular
germ cell cancer [27] and cervical cancer by copy number gain
[8]. In the cervical cancer study, CLPTM1L emerged from the 5 p
locus as having expression patterns that correlated with copy
number gain. Another recent study of copy number and
expression changes in cervical cancer cell lines revealed that with
copy number gain across 5 p, CLPTM1L expression was
increased approximately 5 fold over normal cervical epithelial
cells, while expression of the other genes at 5 p15.33 was not
changed [9]. The TERT gene is also within this genetic region. In
analysis of SNPs in the 5 p region, we have found that lung cancer
associated SNPs are not associated with telomere length (data not
shown), in agreement with two other studies [28,29]. In contrast, a
study by Rafnar et al. showed an association (p=0.017 and 0.027,
respectively) between 5 p variants (rs401681 and rs2736098) and
telomere length, although this effect was only seen when women
older than 75 years with homozygous genotypes were included
Figure 3. DNA damage induced apoptosis is regulated by CLPTM1L. A) Annexin V binding by flow cytometry of A549 cells with CLPTM1L
knockdown after 48 hours treatment with cisplatin. B) Relative caspase 3/7 activity in H838 cells with CLPTM1L knockdown after 48 hours treatment
with cisplatin. Error bars represent one standard deviation from the mean. **- p,0.01 * - p,0.02 by two-tailed Student’s T-Test. C) Micrographs of
A549 cells with CLPTM1L knockdown after 24 hours treatment with 50 mM cisplatin showing increased genotoxic cell death upon loss of CLPTM1L.
doi:10.1371/journal.pone.0036116.g003
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CLPTM1L or TERT have been identified. It is plausible that both
TERT and CLPTM1L contribute to susceptibility at this locus,
having a co-founder effect. A recent study [5] provides multiple
lines of evidence that the lung cancer association of rs31489 in the
CLPTM1L gene is an independent observation from the
association of rs2376100 in the TERT gene. The most recent
dense genotyping study of 5 p15.33 found multiple associations at
5p15.33, with the region of association being centered over
CLPTM1L [7]. Our previous analysis shows that rs31489 is the
variant most strongly associated with familial lung cancer at this
locus. The current study indicates that CLPTM1L also plays an
important functional role in relation to cancer, and that this gene
may to be at least partially responsible for the association of
variants in the 5p15.33 region with lung cancer. Continued efforts
to further define the genetic variation driving lung cancer
susceptibility in this genetic region are an important next step in
evaluating the relationship of CLPTM1L and other genes in the
region with lung tumor susceptibility.
Common overexpression of CLPTM1L in lung tumors and a
functional role in genotoxic stress induced apoptosis identify
CLPTM1L as an important factor influencing survival of DNA
damaged tumor cells and potentially lung cancer susceptibility.
Targeting CLPTM1L as well as Bcl-xL may prove to be useful
approaches to chemoprevention and lung cancer therapy.
Targeting these anti-apoptotic proteins may also have potential
for sensitization of tumors to traditional chemotherapies and
radiotherapies.
Materials and Methods
RT-Quantitative Real-Time PCR
Patient matched tumor and tumor-adjacent normal RNA
samples were obtained from the Tissue Procurement Core at
Washington University in St. Louis under protocol approved by
the Institutional Review Board at Washington University in St.
Louis School of Medicine, Human Research Protection Office.
Written consent was obtained from all patients participating in this
tissue bank. RNA was isolated from cell lines using Tri-zol reagent
and protocols (Invitrogen, Carlsbad, CA). Quantitative real-time
PCR (qPCR) was conducted using the method as described
previously (Chaparro, Wen et al. 2005). Briefly, one microgram of
Figure 4. Modulation of Bcl-xL expression is required for apoptotic effects of CLPTM1L. A) Western blotting for apoptotic regulators in
A549 cells with CLPTM1L knockdown after treatment with cisplatin showing decreased Bcl-xL expression upon loss of CLPTM1L. Bcl-xL blots for two
separate representative clonal populations of A549 cells with CLPTM1L knockdown (#1 and #2) are shown. B) Graphic representation of Bcl-xL
expression in cells with CLPTM1L knockdown from three separate clonal populationsA549. Error bars represent one standard deviation from the
mean. * - p,0.003 by Student’s T-Test C) Western blots confirming expression of exogenous Bcl-xL in A549 cells with CLPTM1L knockdown. D)
Relative viable cell counts in A549 cells with CLPTM1L knockdown and ectopic Bcl-xL expression after treatment with cisplatin demonstrating the
abolition of apoptotic effect of CLPTM1L loss upon ectopic Bcl-xL expression.
doi:10.1371/journal.pone.0036116.g004
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SuperScript First-Strand Synthesis system for RT-PCR (Invitro-
gen, Carlsbad, CA). Quantitative RT-PCR assay was done using
the SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA). One microliter of cDNA was added to a 25 mL total
volume reaction mixture containing water, SYBR Green PCR
Master Mix, and primers. Each real-time assay was done in
duplicate on a BioRad MyIQ machine. Data were collected and
analyzed with Stratagene Mx3000 software. The b-actin gene
(Actb) was used as an internal control to compute the relative
expression level (DCT) for each sample. Primer set efficiency and
linearity was calculated, and normalization was performed in
accordance with MIQE guidelines. The fold change of gene
expression in tumor tissues as compared to the paired normal
tissues was calculated as 2
d, where d = DCT normal – DCT tumor.
Microarray Analysis
Expression microarrays were performed using the Illumina
HumanWG-6 V3 platform, which contains 48,800 probes
corresponding to 20,700 unique genes. RNAs (500 ng) were
labeled and hybridized to the BeadChip arrays as specified by the
manufacturer (www.illumina.com). Array data were pre-processed
with the MBCB algorithm (Ding, LH et al, Nucl. Acids Research,
2008, 36:e58) and differential expression was determined by
calculating fold change and T test.
Cell Culture, Knockdown and Overexpression
A549 cells (ATCC, Manassas, VA), recently authenticated by
Genetica Laboratores, Inc. (Cinncinati, OH), were cultured in
RPMI-1640 plus 10% FBS (Invitrogen, Carlsbad, CA). Cells were
transduced with lentiviral short-hairpin RNA (shRNA) vectors
based on the pLKO.1 vector and designed to specifically target
human CLPTM1L transcript (Sigma, St. Louis). Empty vector or
vector knocking down CLPTM1L transcript were first packaged in
293T cells (Orbigen, San Diego, CA) with helper plasmids and
then transduced into A549 cells with 8 mg/ml Polybrene (Sigma,
St. Louis, MO). Media was replaced 24 hours after transduction,
and cells were split 1:4 48 hours after transduction. At 72 hours
post transduction, cells harboring lentiviral constructs were
selected with 1 mg/ml puromycin for 2–4 days, until mock
infected cells were dead. Surviving cells were pooled.
pBABEpuro expression vector or pBABEpuro:CLPTM1L,
cloned by PCR from pOTB7-CLPTM1L, (Thermo Scientific),
into EcoRI/SalI sites of pBABE-puro, was transfected into H1299
cells. Transfected cells were selected with puromycin until mock
transfected cells were dead.
pSSFV Bcl-xL expression vector (Addgene plasmid 8749) or
empty vector was transfected into cells with and without
knockdown of CLPTM1L as described above. Transfected cells
were selected with Geneticin (Invitrogen, Carlsbad, CA).
Viability Assay
Cells stably expressing shRNA vectors as described above were
seeded onto 12-well tissue culture dishes at equal densities of
approximately 50% in triplicate. After attachment overnight
followed by 48 hours of treatment with the indicated concentra-
tions of cisplatin (Sigma, St. Louis, MO) dissolved in media,
camptothecin (Sigma, St. Louis. MO) dissolved in DMSO (Sigma,
St. Louis, MO), or DMSO solvent alone. DMSO concentrations
in culture media were kept consistent and were at or below 0.08%.
Cells were assayed for viable cell numbers by trypan blue staining
and counted on a Countess automated cell-counter (Invitrogen,
Carlsbad, CA). For camptothecin assays, cell viability was
measured by Cell Titer 96 Aqueous One Solution Cell Prolifer-
ation Assay (MTS) on 24 well tissue culture plates in triplicate. P-
values were determined by one-tailed Student’s T-Test.
Flow Cytometry
The indicated cell lines were treated for 24 hours with the
indicated concentrations of cisplatin on 10 cm tissue culture
dishes. 10
6 cells were washed and suspended in PBS and stained
with Annexin V-FITC. Cells in staining solution were diluted with
500 ml PBS and analyzed on a Coulter flow cytometer.
Caspase 3/7 Assay
The indicated cell lines were plated at densities of 5610
4 cells
per well of a 12 well tissue culture plate and treated as indicated
with genotoxic agents after attachment overnight. Caspase 3 and 7
activity was measured using SensoLyteH Homogeneous Rh110
Caspase - 3/7 Assay Kit (Anaspec, Fremont, CA).
Western Blotting
The indicated cell lines were treated with cisplatin at the
indicated concentrations on 6-well plates for 72 hours. Cells were
lysed with 100 ml of 1X NP40 lysis buffer containing proteinase
inhibitors, sheared 10 times with a 28 gauge needle, spun at
16,0006g for 30 minutes, normalized by protein concentration as
determined by the Bradford method, and the supernatant boiled
for 10 min. 20 ml of normalized lysate was resolved by SDS-PAGE
and immunoblotting analyzed with indicated antibodies. The
following antibodies were used: rabbit anti-CLPTM1L (Sigma, St.
Louis, MO), rabbit anti-beta tubulin (Sigma, St. Louis, MO),
mouse anti-Bcl2 clone 124 (Dako, Carpinteria, CA), rabbit anti-
Bax #2774 (Cell Signaling, Boston, MA), mouse anti-p53 (Ab-1)
(Oncogene, San Diego, CA), Bcl-xL – rabbit Bcl2L1 (AbCam,
Cambridge, MA). Quantitation of Western analyses of three
independent cultures was done using Image J software available
online from NIH at http://rsbweb.nih.gov. P-values determined
by one-tailed student’s T-Test.
COMET Assay
The gel electrophoresis based method for detection of DNA
damage was conducted was modified from Olive, et al. Nature
Protocols 1, 23 – 29 (2006). Cells were treated with indicated
concentrations of NNK, cisplatin or DMSO solvent 0.1% for 24
hours. Microscope slides were pre-coated with low melting point
agarose (Sigma, St. Louis, MO) 1% in dH2O and dried. One mL
of low melting point agarose 1% in dH2O kept at 40uC was added
to 0.4 mL of a suspension of 2610
4 cells/mL in cold media. The
agarose/cells mix (1mL/slide) was spread on the pre-coated slides.
They were then placed in a lysis solution (2.5 mM NaCl; 0.1 mM
EDTA; 10 mM Tris pH 10, Triton X-100 1%) at 4uC for 2 hours,
washed 3620 min. in electrophoresis solution (300 mM NaOH;
1 mM EDTA,pH .13), and transferred to an electrophoresis tank
in a cold chamber containing electrophoresis solution. A current of
0.45 V/cm was applied for 25 min. The slides were then
neutralized with 365 min washing steps with TE buffer pH 7.5,
and then stained with SYBR Gold (Molecular Probes, Eugene,
OR) in TE buffer. At least twenty-five consecutive nucleoids in the
centre of each slide were photographed and analyzed for tail DNA
content using CASP software. Results are expressed as the Olive
Tail Moment.
Statistical Analysis
Correlation coefficient between percent knockdown and apop-
tosis was determined using the equation:
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where x and y are the sample means average percent knockdown
and average apoptotic index. P-values for correlations were
determined using : Soper, D.S. (2012) "p-Value Calculator for
Correlation Coefficients (Online Software)", http://www.
danielsoper.com/statcalc3
Supporting Information
Figure S1 A) Scatter plot of fold change in TERT expression in
tumors over paired normal tissues on the x-axis, vs. the same for
CLPTM1L expression on the y-axis. B) Scatter plot of relative
TERT expression in tumor cell lines on the x-axis vs. relative
CLPTM1L expression on the y-axis. Relative expression normal-
ized to the average.
(TIFF)
Figure S2 Cell viability as measured by MTS assay and
expressed as absorbance at 490 nm of A549 cells with CLPTM1L
knockdown after 48 hours with a range of doses of camptothecin.
(TIFF)
Figure S3 (A) Scatter plot of percent knockdown of CLPTM1L
in assayed A549 cells versus percent of cells staining positive for
Annexin V as measured by flow cytometry. (B) Scatter plot of
percent knockdown of CLPTM1L in assayed H838 cells versus
Caspase 3/7 activity relative to vector control as measured by
colorimetric Caspase 3/7 assay. Trend lines and r
2 values were
added using Microsoft Excel and as describe in the methods
section.
(TIFF)
Figure S4 (A) Representative micrographs of COMET assay for
DNA damage in cells with CLPTM1L knockdown under 0 or
100 mM NNK. (B) DNA damage defined by the average Olive tail
moment under NNK or cisplatin treatment.
(TIFF)
Figure S5 Annotated immunohistochemistry showing
CLPTM1L expression in normal and lung tumor tissues and lung
tumor cell lines from the Human Protein Atlas. Staining was
scored as follows: 0= negative, 1= weak, 2= moderate, 3=
strong.
(TIFF)
Table S1 Characteristics of the study population used for
matched tumor and normal lung tissue expression studies.
(TIFF)
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